A busy two weeks in life science. The biggest story of the period is a phase 3 trial result in pancreatic cancer that has generated more enthusiasm than almost any oncology readout in recent memory. Here’s what happened and why it matters.
Daraxonrasib Doubles Survival in Metastatic Pancreatic Cancer
On April 13, Revolution Medicines announced that their KRAS inhibitor daraxonrasib had met its primary endpoints in the phase 3 RASolute 302 trial, reducing the risk of death by 60% compared with standard chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).
The numbers are striking. Median overall survival was 13.2 months with daraxonrasib versus 6.7 months with chemotherapy (hazard ratio 0.40, p < 0.0001). Pancreatic cancer has been one of the most treatment-resistant cancers for decades; a median OS under seven months in second-line PDAC has been the durable benchmark that countless trials have failed to meaningfully improve on. Doubling it is genuinely significant.
Daraxonrasib is a RAS(ON) multi-selective inhibitor, meaning it inhibits multiple RAS mutant forms including the KRAS G12D and G12V mutations that drive the majority of pancreatic cancers. Revolution also reported progression-free survival and response rate improvements that were consistent with the OS data.
Revolution plans to submit an NDA to the FDA and to present the full data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in June.
What this means for researchers: KRAS has been called “undruggable” for most of the past three decades. The approval of sotorasib and adagrasib for KRAS G12C in lung cancer showed the target was tractable, but G12C is rare in pancreatic cancer. Daraxonrasib’s multi-selective approach may open a therapeutic window for the KRAS variants that actually drive PDAC, one of the cancers with the most urgent unmet need. The RASolute 302 data will likely reshape how second-line pancreatic cancer is treated and accelerate a substantial body of follow-on research into RAS pathway combination strategies.
FDA Approves Foundayo (Orforglipron): An Oral GLP-1 With No Food Restrictions
On April 1, the FDA approved Eli Lilly’s Foundayo (orforglipron), an oral GLP-1 receptor agonist for adults with obesity or overweight with at least one weight-related comorbidity. The approval arrived 294 days before its PDUFA date, under the FDA’s National Priority Voucher program.
Orforglipron is the first oral GLP-1 that can be taken any time of day without food or water restrictions. Oral semaglutide (Rybelsus), by contrast, requires fasting for 30 minutes after ingestion with a small amount of water. That restriction is a meaningful adherence barrier. In the ATTAIN-1 trial, patients on the highest dose of orforglipron who remained on treatment lost approximately 12.4% of body weight versus 0.9% with placebo.
The price point is notable. Self-pay pricing starts at $149 per month for the lowest dose, with commercially insured patients potentially paying as little as $25 monthly. That’s below the launch pricing of injectable semaglutide and tirzepatide, though formulary coverage will ultimately determine what most patients pay.
What this means for researchers: GLP-1 biology continues to be one of the most commercially productive research areas in pharma. The oral formulation development challenge has been partly solved. The interesting open questions now are long-term metabolic outcomes data, cardiovascular benefit (injectable GLP-1s have shown consistent CV benefit; whether oral formulations achieve similar exposure and benefit is not yet fully established), and the rapidly expanding pipeline of GLP-1 combination and next-generation agents across multiple disease areas beyond obesity.
The GLP-1/Alzheimer’s Story Gets More Complex
Separate from orforglipron’s approval, the same two-week period saw substantial discussion following the Lancet publication of the EVOKE trial results, which showed that oral semaglutide did not slow clinical progression of early Alzheimer’s disease over two years. The disconnect between biomarker effects and clinical outcomes in that trial raises important questions about GLP-1 CNS penetration and the appropriate timing of intervention in neurodegeneration.
For a full breakdown of the EVOKE results and what they mean for the field, see Semaglutide Fails to Slow Alzheimer’s Disease in Phase 3 EVOKE Trials.
Catch Up on Earlier April Stories
For the first week of April coverage, including the Orca-T stem cell transplant data and the Hunter syndrome therapy approval, see Life Science News: Early April 2026.